Document is current
Any future updates will be listed below
-
Authors
Lütje, Susanne
Schäfer, Laura
Altunay, Betül
Hertel, Fabian
Morgenroth, Agnieszka
Mottaghy, Felix M.
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (331065168)
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 20 June 2025
First Online: 15 July 2025
Declarations
:
: Not applicable.
: Felix M. Mottaghy is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision HealthCare LLC. He is also supported by the German Research Foundation (DFG) within the framework of the Research Training Group 2375 “Tumor-targeted Drug Delivery” (grant 331065168), the Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (project 445703531). In addition, his research is funded by the German Federal Ministry of Research and Education (project 16GW0319K). Moreover, he is an editor in the European Journal of Nuclear Medicine and Molecular Imaging.
